Laser therapy treatment

 

(57) Abstract:

Usage: the invention relates to medicine and can be used for the treatment of patients HIBS. The inventive laser unit, made of power and control, emitter semiconductor laser which includes a nozzle consisting of a waveguide optical hub radiation, coupled with the light guide. Waveguide optical hub radiation is a segment of optical fiber, made in the form of a truncated cone, the outer conical surface of which is coated with alternating quarter-wave layers of dielectrics with two different values of refractive index. The first layer adjacent the surface of the cone, and all the odd-numbered layers have a refractive index smaller than that of the material of the cone, and all the even-numbered layers of dielectric - refractive index greater than that of the odd-numbered layers. 2 Il., table 2.

The invention relates to medicine and can be used in medical practice to improve the laser beam on the biologically active points of the body of the patient.

Known laser system used in therapeutic practices, on the basis of low-energy helium-neon laser installation "Berry", "RIP-01", and on the basis of semiconductor lasers install "Pattern", "Katarsis-001 L", etc.

So, in the paper "Application of radiation of helium-neon laser for the treatment of GIBS" (Moscow, 1987) described laser unit, consisting of radiator, power supply, indicator power density of the radiation. The disadvantage of this device is the high beam divergence of the laser radiation reaching tens of degrees, which defines a large spot size on the biological tissue and low power density of the radiation. The consequence of this is a small penetration depth of the laser beam on the biologically active points of the body.

In this work taken as a prototype of a laser therapeutic apparatus "Pattern", which is designed to study the influence of low-intensity laser pulse near IR spectral region from the semiconductor emitters in biological tissue. The apparatus consists of a power supply, control and emitter semiconductor laser.

The lack of "Pattern" is the low degree of penetration of the laser radiation in the tissue.

The purpose of the invention ical tissue.

New therapeutic laser system, consisting of a standard power supply and control, emitter semiconductor laser, characterized in that to increase the depth of penetration of laser radiation in biological tissue contains a nozzle that includes a waveguide optical hub radiation, connected to the light guide.

In Fig. 1 shows a block diagram of a laser therapeutic setting; Fig. 2 optical waveguide concentrator.

The unit consists of a power supply and control 1, the emitter semiconductor laser 2, the optical waveguide concentrator radiation 3 with a multilayer dielectric coating 5 and the optical fiber 4. Waveguide optical hub radiation 3 is a segment of optical fiber, made in the form of a truncated cone, the outer conical surface of which is coated with alternating quarter-wave layers of dielectrics with two different values of refractive index. He connected with the optical fiber 4 via the docking station 6. Nozzle therapeutic laser setup consists of an optical waveguide concentrator radiation 3, which is a segment of the fiber, viletobodo 4.

The base diameter of the cone (entrance aperture) equal to the width of the crystal oscillator semiconductor laser 2, and the diameter of the apex of the cone (output aperture) equal to the diameter of the fiber.

Included in the optical waveguide concentrator radiation 3 a highly divergent beam of laser radiation due to multiple reflections from inside covered with layers of dielectric surface of a truncated cone and due to the phenomena of total internal reflection of the light is concentrated on the entrance end face of the hub, and coupled with the light guide.

Outside the hub radiation 3 is covered with alternating quarter-wave layers of dielectric with two different values of refractive index. The first layer adjacent to the surface of the cone, and subsequent odd-numbered layers have a refractive index of n1less than the refractive index of the material of the cone n0, i.e., n1<n. This ensures total internal reflection of laser radiation from the boundary between the cone of the first coating layer for rays propagating at small angles to the axis of the cone, q <owhereo- maximum angle that can be determined from the equation

< / BR>
where upojenie inside from alternating layers of dielectric, the optical thickness of each of which is equal to a quarter wavelength of the laser, due to the interference of light in the layers. The values of refractive index for the first and every odd layer of n1and each even layer of n2and n1<n. The layers are as follows: the first applied layer with a value of refractive index n1the following n2and so on

For a given laser therapeutic install the cone was made of quartz (n0= 1,46), as odd dielectric layers were used magnesium fluoride MgF2with a refractive index of n1=1,38, and even zinc sulfide ZnS with n2=2,35. Also, can be applied to other pairs of substances, for example: LiF Zns, MgF2- ZrO2and other

The angle at the vertex of the cone depends on the divergence of the laser radiation and the refractive indices of the materials of the hub and dielectric layers.

The device operates as follows.

When turning on the power supply unit 1 emitter semiconductor laser 2 generates a highly divergent beam of laser radiation. The specified beam enters the input end of the optical waveguide concentrator islet in the light guide 4.

Through the optical fiber 4 laser radiation is conducted to the biologically active points of the patient. The exposure time is 1 point 1.5 min, in the course of treatment the patient is set to 15 procedures.

Will hold the justification of increasing the efficiency of therapeutic laser installation by calculating the physical parameters.

Physical parameters of the calculation in the usual method of treatment of HIBS semiconductor device Pattern, the following.

A typical spot size of the laser radiation on the body of the patient 4 mm to 6 mm, therefore the area of the spot:

S=AB

where S is the area of the macula;

A and B are the lengths of the sides of the spot, hence in our case:

S=4 MM6 mm=24 mm2.

The power density of the radiation spots:

< / BR>
where Po-power,

S size of the spot,

therefore, in our case:

.

Thus the penetration depth of the laser beam is about 2 mm

The use of the claimed therapeutic laser installation and nanovolokno fiber brand CPO, allows to obtain a spot on the patient's body with a diameter of 0.6 mm, and its area is:

S = R2,

where S is the area of the spot,

R is the radius of the spot,

therefore:

The
Tue, as the power density increases and will equal:

< / BR>
where Popower,

S size of the spot,

therefore:

.

Thus the penetration depth of the laser beam is increased to 50 mm, as it increases the power density at the fiber output, and the medical effect.

We offer laser therapy treatment was tested in 25 patients HIBS. In the result, the laser beam penetrates to a greater depth, improves impact on the BAT and to the lesion.

At the same time, according to I. M. Korochkina (1987), using a standard laser therapeutic setting, 5-7 procedure was observed frequent attacks of illness. This kind of exacerbation of the disease was observed 2-3 days, but in the process of treatment it was repeated with multiplicity, corresponding to the beginning of the 1st exacerbation (6, 12, 18 days).

In patients whose treatment was carried out offer laser therapeutic device, such phenomena were not observed.

Simultaneously, we investigated lipid peroxidation of blood by the method of chemoluminescence before treatment, after 10 treatments and 15 procedures after lazarat the existence occurs as a result of disruption of the physiological antioxidant system, when the chain snowballing process of free-radical oxidation of lipids causes the complex pathological manifestations, called the syndrome peroxidation.

Based on the analyses of the obtained data it was concluded that the best effect in patients of HIBS came under the influence of the effects of the claimed therapeutic laser setup with a pulse frequency of 80 Hz and a radiation power of 2 watts. With these parameters, taking into account the increase of the penetration depth of the laser beam, there was no pain, faster improvement of ECG. Side effects with this method of treatment were observed. In the process of treating pain decreases until complete disappearance.

Contraindications to treatment:

1. The tendency to bleed.

2. Tumors of various etiologies.

3. The high temperature.

4. The open form of tuberculosis.

5. Diseases of the blood.

6. Thyrotoxicosis.

7. Acute infectious diseases.

8. Congestive heart failure II-III degree.

Example 1. Patient Z. 45 years old, was admitted to cardiology Department of the railway hospital with a diagnosis of HIBS, stable stenocardia the Oli, occur during exercise. ECG normal position of the electrical axis of the heart, the sinus rhythm, C. C. C. 67 minutes Hypertrophy of the myocardium of the left ventricle with congestion, diffuse changes of a myocardium. When performing exercise tests marked threshold load amounted to 440 KGM/min

The appointed course of laser therapy on biologically active points (the top. CR. gr. the upper hand. tone.) the claimed laser therapeutic device. 5-7 procedure exacerbation of the disease was not observed. After 7 treatments came analgesic effect (see tab. 1).

Example 2. Patient M. aged 47, was treated at the cardiology Department of the railway hospital.

Diagnosis: HIBS, myocardial infarction, stable angina II FC, extrasystole, NC Art. I

At admission, there were complaints about squeezing pain in the heart that occur during exercise (up to 5-6 nitroglycerin tablets per day), shortness of breath.

From the anamnesis it follows that in 1987, the patient suffered a myocardial infarction.

Objectively: the skin is a normal color, peripheral edema no. Hell 140/90 mm RT.article H. S. S. 80 in/min Borders of the heart: right on the right edge of the GRU is CNY, muted, accent II tone. Extrasystole in 1-2 minutes Auscultative vesicular breathing. The gastrointestinal tract without pathology.

ECG sinus rhythm. Signs of left ventricular hypertrophy. Scar on the back wall of the left ventricle. Ischemia in the posterior-lateral wall ("-" ST in leads II, III; and YF; Y5; Y6).

When performing exercise tests marked average tolerance to physical load: 440 KGM/min, on the 9 th minute appeared anginal pain. The patient against medical therapy (nitrates 106 mg, obzidan 122 mg) administered a course of laser therapy, was taken blood on lipid peroxidation (see tab. 2).

Biochemical indices had positive dynamics. As a result of treatment showed a good clinical effect, disappeared anginal pain, interruptions in the heart. The patient had no further use nitroglycerin, after 15 days the patient was cancelled nitrates, dose blockers reduced to 4 mg ECG sinus rhythm; ST "+" II, III; and YF, Y5-Y6. The rest is unchanged. The observed increase in tolerance to physical load: power threshold load was increased to 660 KGM/min it Should be noted that sick what rotation offer laser therapy treatment through the introduction of optical waveguide concentrator radiation and the light guide RG - 600 has the following advantages:

provided the increase of the penetration depth of the laser beam to the biologically active points of the patient by increasing the power density at the output;

achieves small size and simplicity of the device in operation;

creates the possibility of using the installation at home.

Laser therapy treatment that contains the power supply and the control emitter semiconductor laser and the nozzle of the light guide, characterized in that the attachment of the light guide is made in the form of a segment of fiber in the form of a truncated cone, with the outer conical surface of the nozzle is covered with alternating quarter-wave dielectric layers with two different values of the refractive index, the first layer adjacent to the conical surface, and all odd-numbered layers have a refractive index less than that of the material of the nozzle, and all the even-numbered layers refractive index greater than that of the odd-numbered layers.

 

Same patents:

The invention relates to optical observation devices and can be used in cases when the input part of the Supervisory device is located at a considerable distance from the observer, for example for monitoring of a helicopter cabin space under the cabin of the helicopter

The invention relates to devices, fiber optics and can be used to connect the optical fiber with another optical fiber or optical element, for example with gradient lens

The invention relates to the field of medical technology and can be used in the treatment of cardiovascular, cancer, allergic and other diseases in which a positive effect of UV-irradiation of blood
The invention relates to medicine, namely to endocrinology, and can be used in the treatment of autoimmune thyroiditis

The invention relates to a physiotherapeutic device and method for influencing the living cells of the body by percutaneous electroneurostimulation and infrared radiation used in medicine to treat a wide range of diseases
The invention relates to medicine, namely to endocrinology, and can be used for the prevention and treatment of diabetic nitroaromatic

The invention relates to medicine, namely to therapy and neurology and can be used in the treatment of headache

The invention relates to methods and devices for cosmetic, hygienic and medical applications, namely the combined methods and devices for hair care and skin
The invention relates to medicine, namely to methods of treatment of inherited diseases of metabolism of mucopolysaccharides
The invention relates to medicine, particularly cardiology

The invention relates to medicine, namely to gynecology, and can be used for the treatment of female infertility caused by tubal obstruction inflammatory origin

FIELD: medicine.

SUBSTANCE: method involves introducing 0.1-0.3 ml of photosensitizing gel preliminarily activated with laser radiation, after having removed neovascular membrane. The photosensitizing gel is based on a viscoelastic of hyaluronic acid containing khlorin, selected from group containing photolon, radachlorine or photoditazine in the amount of 0.1-2% by mass. The photosensitizing gel is in vitro activated with laser radiation having wavelength of 661-666 nm during 3-10 min with total radiation dose being equal to 100-600 J/cm2. The gel is introduced immediately after being activated. To compress the retina, vitreous cavity is filled with perfluororganic compound or air to be further substituted with silicon oil. The operation is ended with placing sutures on sclerotomy and conjunctiva areas. Compounds like chealon, viscoate or hyatulon are used as viscoelastic based on hyaluronic acid. Perfluormetylcyclohexylperidin, perfluortributylamine or perfluorpolyester or like are used as the perfluororganic compound for filling vitreous cavity.

EFFECT: excluded recurrences of surgically removed neovascular membrane and development of proliferative retinopathy and retina detachment; retained vision function.

3 cl, 5 dwg

FIELD: medicine.

SUBSTANCE: method involves making incision in conjunctiva and Tenon's capsule of 3-4 mm in size in choroid hemangioma projection to sclera 3-4 mm far from limb. Tunnel is built between sclera and Tenon's capsule to extrasclerally introduce flexible polymer magnetolaser implant through the tunnel to the place, the choroid hemangioma is localized, after performing transscleral diaphanoscopic adjustment of choroid hemangioma localization and size, under visual control using guidance beam. The implant has permanent ring-shaped magnet in the center of which a short focus scattering lens of laser radiator is fixed. The lens is connected to light guide in soft flexible envelope. The permanent implant magnet is axially magnetized and produces permanent magnetic field of 2-3 mTesla units intensity. It is arranged with its north pole turned towards the choroid hemangioma so that extrascleral implant laser radiator disposition. The other end of the implant is sutured to sclera 5-6 mm far from the limb with two interrupted sutures through prefabricated openings. The implant is covered with conjunctiva and relaxation sutures are placed over it. Light guide outlet is attached to temple using any known method. 0.1-1% khlorin solution is injected in intravenous bolus dose of 0.8-1.1 mg/kg as photosensitizer and visual control of choroid hemangioma cells fluorescence and fluorescent diagnosis methods are applied. After saturating choroid hemangioma with the photosensitizer to maximum level, transscleral choroid hemangioma laser radiation treatment is carried out via laser light guide and implant lens using divergent laser radiation at wavelength of 661-666 nm with total radiation dose being equal to 30-120 J/cm2. The flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, samarium-iron-nitrogen or neodymium-iron-boron system material. The photosensitizer is repeatedly intravenously introduced at the same dose in 2-3 days after the first laser radiation treatment. Visual intraocular neoplasm cells fluorescence control is carried out using fluorescent diagnosis techniques. Maximum level of saturation with the photosensitizer being achieved in the intraocular neoplasm, repeated laser irradiation of the choroid hemangioma is carried out with radiation dose of 30-60 J/cm2.

EFFECT: enhanced effectiveness of treatment.

4 cl

FIELD: medicine.

SUBSTANCE: method involves creating tunnel between sclera and Tenon's capsule in intraocular neoplasm projection. Intraocular neoplasm localization and size is adjusted by applying transscleral diaphanoscopic examination method. 0.1-0.3 ml of photosensitizing gel based on viscoelastic of hyaluronic acid, selected from group containing chealon, viscoate or hyatulon, is transsclerally introduced into intraocular neoplasm structure using special purpose needle in dosed manner. The photosensitizing gel contains khlorin, selected from group containing photolon, radachlorine or photoditazine in the amount of 0.1-1% by mass. Flexible polymer magnetolaser implant is extrasclerally introduced into the built tunnel in intraocular neoplasm projection zone under visual control using guidance beam. The implant has permanent ring-shaped magnet axially magnetized and producing permanent magnetic field of 3-4 mTesla units intensity, in the center of which a short focus scattering lens of laser radiator is fixed. The lens is connected to light guide in soft flexible envelope. The implant is arranged with its north pole turned towards the intraocular neoplasm so that implant laser radiator lens is extrasclerally arranged in intraocular neoplasm projection zone. The implant light guide is sutured to sclera 5-6 mm far from the limb with single interrupted suture. The implant is covered with conjunctiva and relaxation sutures are placed over it. Light guide outlet is attached to temple using any known method. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, transscleral intraocular neoplasm laser radiation treatment is carried out via laser light guide and implant lens using divergent laser radiation at wavelength of 661-666 nm. The treatment course being over, the flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, neodymium-iron-boron or samarium-iron-nitrogen. 0.1-1% khlorin solution as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is additionally intravenously introduced in 2-3 days at a dose of 0.8-1.1 mg/kg and repeated laser irradiation of the intraocular neoplasm is carried out with radiation dose of 30-45 J/cm2 15-20 min later during 30-90 s.

EFFECT: complete destruction of neoplasm; excluded its further growth.

4 cl

FIELD: medicine.

SUBSTANCE: method involves applying transscleral diaphanoscopic examination method for adjusting intraocular neoplasm localization and size. Rectangular scleral pocket is built 2/3 times as large as sclera thickness which base is turned from the limb. Several electrodes manufactured from a metal of platinum group are introduced into intraocular neoplasm structure via the built scleral pocket. Next to it, intraocular neoplasm electrochemical destruction is carried out in changing electrodes polarity with current intensity of 100 mA during 1-10 min, and the electrodes are removed. Superficial scleral flap is returned to its place and fixed with interrupted sutures. 0.1-2% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, transpupillary laser radiation of 661-666 nm large wavelength is applied at a dose of 30-120 J/cm2. the operation is ended with placing sutures on conjunctiva. Platinum, iridium or rhodium are used as the metals of platinum group. The number of electrodes is equal to 4-8. 0.1-1% khlorin solution, selected from group containing photolon, radachlorine or photoditazine, is additionally repeatedly intravenously introduced in 2-3 days at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, repeated laser irradiation of the intraocular neoplasm is carried out with radiation dose of 30-45 J/cm2.

EFFECT: complete destruction of neoplasm; excluded tumor recurrence; reduced risk of tumor cells dissemination.

3 cl, 3 dwg

FIELD: medicine.

SUBSTANCE: method involves preparation dental surface, covering it with 30% aqueous solution of silver nitrate and recovery agent for precipitating insoluble silver salts. Silver salts precipitation is carried out by exposing silver nitrate covering tooth surface with halogen radiation of the kind produced by halogen lamp of 12 W or 75 W having spectral bandwidth of 400…500 nm provided with light guide for concentrating luminous flux for 60 s.

EFFECT: enhanced effectiveness of treatment; localized treatment; reduced risk of complications and stress action upon child.

FIELD: medicine.

SUBSTANCE: the present innovation deals with treating vascular cutaneous neoplasms, such as nevus flammeus and gemangiomas. Light-thermal impact at energy ranged 39-47 J/sq. cm should be performed in two stages, and between them, 2-3 wk after the onset of vascular resistance at the first stage one should perform beta-therapy daily for 2-3 d at single dosage being 20 g. Then, 3 wk later it is necessary to conduct the second stage of light-thermal impact by starting at energy value being 42 J/sq. cm, not less. The method enables to shorten therapy terms due to applying combined method to affect vascular cutaneous neoplasms.

EFFECT: higher therapeutic and cosmetic effect.

1 ex

FIELD: medicine.

SUBSTANCE: method involves intravitreously introducing two electrodes into intraocular neoplasm after carrying out vitrectomy and retinotomy to expose the intraocular neoplasm. The electrodes are manufactured from platinum group metal. Electrochemical destruction is carried out with current intensity of 100 mA during 1-10 min or 10 mA during 10 min in changing electrodes polarity and their position in the intraocular neoplasm space, and the electrodes are removed. 0.1-1% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, intravitreous laser radiation is carried out in parallel light beam of wavelength equal to 661-666 nm is applied at a dose of 30-120 J/cm2.The transformed retina and tumor destruction products are intravitreally removed. Boundary-making endolasercoagulation of retinotomy area is carried out after having smoothed and compressed retina with perfluororganic compound. The operation is finished with placing sutures on sclerotomy and conjunctiva. Platinum, iridium or rhodium are used as the platinum group metals. Another embodiment of the invention involves adjusting position and size of the intraocular neoplasm in trans-scleral diaphanoscopic way. Rectangular scleral pocket is built above the intraocular neoplasm to 2/3 of sclera thickness with its base turned away from limb. Several electrodes are introduced into intraocular neoplasm structure via the built bed. The electrodes are manufactured from platinum group metal. Electrochemical destruction is carried out with the same current intensity in changing electrodes polarity and their position in the intraocular neoplasm space, and the electrodes are removed. Superficial scleral flat is returned to its place and fixed with interrupted sutures. 0.1-1% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg after having carried out vitrectomy and retinotomy. Visual control of intraocular neoplasm cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, intravitreous laser radiation is carried out in parallel light beam of wavelength equal to 661-666 nm is applied at a dose of 30-120 J/cm2. The transformed retina and tumor destruction products are intravitreally removed using vitreotome. Boundary-making endolasercoagulation of retinotomy area is carried out after having smoothed and compressed retina with perfluororganic compound. The operation is finished with placing sutures on sclerotomy and conjunctiva. Platinum, iridium or rhodium are used as the platinum group metals. The number of electrodes is equal to 4-8.

EFFECT: reduced risk of metastasizing.

4 cl, 13 dwg

FIELD: medicine.

SUBSTANCE: method involves building tunnel to posterior eyeball pole in inferoexterior and superexterior quadrants. The tunnel is used for implanting flexible polymer magnetolaser implant to the place, the subretinal neovascular membrane is localized. The implant has a permanent magnet shaped as a cut ring and is provided with drug delivery system and a short focus scattering lens of laser radiator connected to light guide. The permanent implant magnet is axially magnetized and produces permanent magnetic field of 5-7 mTesla units intensity. It is arranged with its north pole turned towards sclera at the place of the subretinal neovascular membrane projection with extrascleral arrangement of laser radiator lens membrane being provided in the subretinal neovascular membrane projection area. The other implant end is sutured to sclera 5-6 mm far from the limb via holes made in advance. The implant is covered with conjunctiva and retention sutures are placed thereon. Light guide and drug supply system lead is attached to temple with any known method applied. Drugs are supplied via the implant drug supply system in retrobulbary way in any order. Triombrast is given in the amount of 0,4-0,6 ml and dexamethasone or dexone in the amount of 0,4-0,6 ml during 3-4 days every 12 h. 0.1-1% aqueous solution of khlorin is intravenously introduced at the third-fourth day after setting the implant as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, at a bolus dose of 0.8-1.1 mg/kg. Visual control of subretinal neovascular membrane cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the subretinal neovascular membrane with the photosensitizer to maximum saturation level, intravitreous, transretinal laser radiation of 661-666 nm large wavelength is applied at general dose of 30-120 J/cm2. The flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, samarium-iron-nitrogen or neodymium-iron-boron system material. The photosensitizer is repeatedly intravenously introduced at the same dose in 2-3 days after the first laser radiation treatment. Visual intraocular neoplasm cells fluorescence control is carried out using fluorescent diagnosis techniques. Maximum level of saturation with the photosensitizer being achieved in the subretinal neovascular membrane via laser light guide and implant lens, repeated laser irradiation of the subretinal neovascular membrane is carried out with radiation dose of 30-60 J/cm2.

EFFECT: accelerated subretinal edema and hemorrhages resorption; regression and obliteration of the subretinal neovascular membrane; prolonged vision function stabilization.

6 cl

FIELD: medicine.

SUBSTANCE: method involves filling vitreous cavity with perfluororganic compound. Two electrodes manufactured from platinum group metal are intravitreally, transretinally introduced into intraocular neoplasm. Electrochemical destruction is carried out with current intensity of 10-100 mA during 1-10 min in changing electrodes polarity and their position in the intraocular neoplasm space, and the electrodes are removed. 0.1-1% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, intravitreous, transretinal laser radiation of 661-666 nm large wavelength is applied at a dose of 30-120 J/cm2 in perfluororganic compound medium. The transformed retina and tumor destruction products are intravitreally removed with perfluororganic compound volume being compensated with its additional introduction. Boundary-making endolasercoagulation of retinotomy area is carried out. The perfluororganic compound is substituted with silicon oil. The operation is ended in placing sutures over sclerotmy areas and over conjunctiva. Perfluormetylcyclohexylperidin, perfluortributylamine or perfluorpolyester or like are used as the perfluororganic compound for filling vitreous cavity. Platinum, iridium or rhodium are used as the platinum group metals.

EFFECT: complete destruction of neoplasm; reduced dissemination risk.

6 cl, 12 dwg

Up!